Non-Regulated LC–MS/MS Bioanalysis in Support of Early Drug Development: A Novartis Perspective
Bioanalysis · 2023
DOI: 10.4155/bio-2022-0204 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioanalysis, 2023. Verfasst von Yunlin Fu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetic Sciences - Drug Disposition, Novartis Institutes for BioMedical Research, One Health Plaza, East Hanover, NJ 07936, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Body Fluids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Scientifically qualified LC-MS/MS methods are essential for the determination of small molecule drug candidates and/or their metabolite(s) in support of various non-regulated safety assessment and in vivo absorption, distribution, metabolism and excretion studies in preclinical development. This article outlines an effective method development workflow to fit for this purpose. The workflow features a 'universal' protein precipitation solvent for efficient sample extraction, a mobile phase additive for managing chromatographic resolution and addressing carryover and an internal standard cocktail to select the best analogue internal standard to track the analyte of interest in LC-MS/MS. In addition, good practices are recommended to prevent bioanalytical pitfalls due to instability, non-specific binding and dosing vehicle-induced matrix effect. Proper handling of non-liquid matrix is also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacokinetic Sciences - Drug Disposition, Novartis Institutes for BioMedical Research, One Health Plaza, East Hanover, NJ 07936, USA.
- Pharmacokinetic Sciences - Drug Disposition, Novartis Institutes for BioMedical Research, Basel, CH-4056, Switzerland.
Zitieren
APA
Fu, Y., Li, W., & Picard, F. (2023). Non-Regulated LC–MS/MS Bioanalysis in Support of Early Drug Development: A Novartis Perspective. Bioanalysis. https://doi.org/10.4155/bio-2022-0204
Vancouver
Fu Y, Li W, Picard F. Non-Regulated LC–MS/MS Bioanalysis in Support of Early Drug Development: A Novartis Perspective. Bioanalysis. 2023. doi:10.4155/bio-2022-0204
BibTeX
@article{Fu2023,
author = {Fu, Yunlin and Li, Wenkui and Picard, Franck},
title = {Non-Regulated LC–MS/MS Bioanalysis in Support of Early Drug Development: A Novartis Perspective},
journal = {Bioanalysis},
year = {2023},
doi = {10.4155/bio-2022-0204}
}
EUVIMED